4 December 2014
ValiRx Plc
("ValiRx" or "the Company")
ValiSeek Scientific Update
Positive Safety and Toxicology Report
ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to provide a further scientific update on the progress of pre-clinical studies at ValiSeek Limited ("ValiSeek"), ValiRx's joint venture company with Tangent Reprofiling Limited ("Tangent") formed to progress the novel cancer treatment drug, VAL401, towards Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.
Further to the update on 2 September 2014, ValiSeek reports on the completion of the pre-clinical toxicology study.
The experiment was a GLP-regulatory standard 28-day repeat dose study at three differing dose levels, including up to 60 times greater than the proposed dose for patients. No adverse effects were seen during the course of the experiment and the positive result advances the project further down the development pathway towards the pivotal clinical trial.
The continuing data analysis from this experiment will confirm the in vivo distribution and exposure (pharmacokinetics) of VAL401. These data will be reported in due course and will support ValiSeek's approach to the regulatory authorities, by ensuring that the proposed clinical trial is initiated at the optimal phase.
Dr Suzanne Dilly, CEO of ValiSeek Limited, commented: "With the drug formulation studies also progressing well, this toxicology package is crucial to our drug fast-track development strategy. It is particularly exciting to be able to report science progressing on schedule and accordingly, allowing our results to map more clearly our regulatory pathway towards a full clinical trial."
Dr Satu Vainikka, CEO of ValiRx plc, added: "The ValiSeek drug development is progressing well and we are very excited about these results."
- ENDS -
For more information, please contact:
ValiRx plc |
Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka |
www.valirx.com |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Daniel Stewart & Company Plc (Broker) |
Tel: +44 (0) 20 7776 6550 |
Martin Lampshire / Mark Treharne |
|
Peckwater PR |
Tel: +44 (0) 7879 458 364 |
Tarquin Edwards |
[email protected] |
Notes for Editors
About SEEK
Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.
Additional information about SEEK is available on the Company's website located at www.seekacure.com
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
